Los Angeles Capital Management LLC Makes New Investment in REGENXBIO Inc. $RGNX

Los Angeles Capital Management LLC bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 125,408 shares of the biotechnology company’s stock, valued at approximately $1,030,000. Los Angeles Capital Management LLC owned about 0.25% of REGENXBIO at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. 22NW LP purchased a new position in REGENXBIO in the 1st quarter worth about $4,781,000. AQR Capital Management LLC grew its stake in REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares in the last quarter. Vanguard Group Inc. grew its stake in REGENXBIO by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after acquiring an additional 487,036 shares in the last quarter. Exome Asset Management LLC bought a new stake in shares of REGENXBIO during the first quarter valued at approximately $2,898,000. Finally, Trexquant Investment LP boosted its holdings in shares of REGENXBIO by 205.6% in the first quarter. Trexquant Investment LP now owns 458,538 shares of the biotechnology company’s stock valued at $3,279,000 after purchasing an additional 308,516 shares during the period. 88.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other REGENXBIO news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the sale, the chief executive officer owned 216,162 shares of the company’s stock, valued at approximately $2,727,964.44. The trade was a 8.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 36,169 shares of company stock worth $416,598. Insiders own 12.79% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Royal Bank Of Canada raised their price objective on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Barclays lowered their target price on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, August 8th. HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Wednesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Monday, September 8th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus target price of $28.63.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $11.60 on Thursday. The business has a fifty day moving average price of $10.90 and a 200 day moving average price of $9.55. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $13.93. The stock has a market capitalization of $587.19 million, a P/E ratio of -3.34 and a beta of 1.23.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. As a group, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.